Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature

Salivary gland carcinomas metastasize to distant organs in 20% of salivary gland malignancies. Applying immunohistochemistry (IHC) measures, salivary gland tumors showed a wide range of oncogene markers expression, including the human epidermoid receptor 2 (Her2/neu), which could be targeted with mo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Belal Firwana, Bassel Atassi, Rim Hasan, Nour Hasan, Ammar Sukari
Formato:	article
Lenguaje:	EN
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2012
Materias:	metastasis salivary gland tumor salivary glands trastuzumab Medicine R
Acceso en línea:	https://doaj.org/article/d52371983cf6451bae53b9ab3cda517e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d52371983cf6451bae53b9ab3cda517e
record_format	dspace
spelling	oai:doaj.org-article:d52371983cf6451bae53b9ab3cda517e2021-12-02T17:59:10ZTrastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature2231-07702249-446410.4103/2231-0770.102282https://doaj.org/article/d52371983cf6451bae53b9ab3cda517e2012-07-01T00:00:00Zhttp://www.thieme-connect.de/DOI/DOI?10.4103/2231-0770.102282https://doaj.org/toc/2231-0770https://doaj.org/toc/2249-4464Salivary gland carcinomas metastasize to distant organs in 20% of salivary gland malignancies. Applying immunohistochemistry (IHC) measures, salivary gland tumors showed a wide range of oncogene markers expression, including the human epidermoid receptor 2 (Her2/neu), which could be targeted with monoclonal antibody. Treating salivary gland tumors, which have Her2/neu over-expression, with trastuzumab was reported in a few case reports. We report a 61-year-old Caucasian male, with a history of salivary gland tumor, who presented after 20 years of complete surgical resection with kidney mass. He was treated as primary renal cell carcinoma, unclassified, with nephrectomy and adjuvant clinical trail where he received placebo. Subsequently, he developed multiple hepatic lesions and retroperitoneal mesenteric lymphadenopathy; CT-guided biopsy revealed adenocarcinoma with Her2/neu, 3+ by IHC. The patient was treated successfully with trastuzumab with near-complete response.Belal FirwanaBassel AtassiRim HasanNour HasanAmmar SukariThieme Medical and Scientific Publishers Pvt. Ltd.articlemetastasissalivary gland tumorsalivary glandstrastuzumabMedicineRENAvicenna Journal of Medicine, Vol 02, Iss 03, Pp 71-73 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	metastasis salivary gland tumor salivary glands trastuzumab Medicine R
spellingShingle	metastasis salivary gland tumor salivary glands trastuzumab Medicine R Belal Firwana Bassel Atassi Rim Hasan Nour Hasan Ammar Sukari Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
description	Salivary gland carcinomas metastasize to distant organs in 20% of salivary gland malignancies. Applying immunohistochemistry (IHC) measures, salivary gland tumors showed a wide range of oncogene markers expression, including the human epidermoid receptor 2 (Her2/neu), which could be targeted with monoclonal antibody. Treating salivary gland tumors, which have Her2/neu over-expression, with trastuzumab was reported in a few case reports. We report a 61-year-old Caucasian male, with a history of salivary gland tumor, who presented after 20 years of complete surgical resection with kidney mass. He was treated as primary renal cell carcinoma, unclassified, with nephrectomy and adjuvant clinical trail where he received placebo. Subsequently, he developed multiple hepatic lesions and retroperitoneal mesenteric lymphadenopathy; CT-guided biopsy revealed adenocarcinoma with Her2/neu, 3+ by IHC. The patient was treated successfully with trastuzumab with near-complete response.
format	article
author	Belal Firwana Bassel Atassi Rim Hasan Nour Hasan Ammar Sukari
author_facet	Belal Firwana Bassel Atassi Rim Hasan Nour Hasan Ammar Sukari
author_sort	Belal Firwana
title	Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
title_short	Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
title_full	Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
title_fullStr	Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
title_full_unstemmed	Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
title_sort	trastuzumab for her2/neu-positive metastatic salivary gland carcinoma: case report and review of the literature
publisher	Thieme Medical and Scientific Publishers Pvt. Ltd.
publishDate	2012
url	https://doaj.org/article/d52371983cf6451bae53b9ab3cda517e
work_keys_str_mv	AT belalfirwana trastuzumabforher2neupositivemetastaticsalivaryglandcarcinomacasereportandreviewoftheliterature AT basselatassi trastuzumabforher2neupositivemetastaticsalivaryglandcarcinomacasereportandreviewoftheliterature AT rimhasan trastuzumabforher2neupositivemetastaticsalivaryglandcarcinomacasereportandreviewoftheliterature AT nourhasan trastuzumabforher2neupositivemetastaticsalivaryglandcarcinomacasereportandreviewoftheliterature AT ammarsukari trastuzumabforher2neupositivemetastaticsalivaryglandcarcinomacasereportandreviewoftheliterature
_version_	1718379017012248576

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature

Ejemplares similares